Fumihiko Hayakawa

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Venues

Cancer medicine

International journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Mina Noura, Sakura Tomita, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa
NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation. Cancer medicine 13 (13) (2024)
Mina Noura, Sakura Tomita, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa
NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation. Cancer medicine 13 (13) (2024)
Chiharu Yamada, Kentaro Okada, Koya Odaira, Mahiru Tokoro, Eisuke Iwamoto, Masashi Sanada, Mina Noura, Syuichi Okamoto, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa
RGS1 and CREB5 are direct and common transcriptional targets of ZNF384-fusion proteins. Cancer medicine 13 (14) (2024)
Mina Noura, Sakura Tomita, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa
NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation. Cancer medicine 13 (13) (2024)
Chiharu Yamada, Kentaro Okada, Koya Odaira, Mahiru Tokoro, Eisuke Iwamoto, Masashi Sanada, Mina Noura, Syuichi Okamoto, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa
RGS1 and CREB5 are direct and common transcriptional targets of ZNF384-fusion proteins. Cancer medicine 13 (14) (2024)
Chiharu Yamada, Kentaro Okada, Koya Odaira, Mahiru Tokoro, Eisuke Iwamoto, Masashi Sanada, Mina Noura, Syuichi Okamoto, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa
RGS1 and CREB5 are direct and common transcriptional targets of ZNF384-fusion proteins. Cancer medicine 13 (14) (2024)
Yukino Kojima, Fumika Kawashima, Takahiko Yasuda, Koya Odaira, Yuichiro Inagaki, Chiharu Yamada, Ami Muraki, Mina Noura, Shuichi Okamoto, Shogo Tamura, Eisuke Iwamoto, Masashi Sanada, Itaru Matsumura, Yasushi Miyazaki, Tetsuhito Kojima, Hitoshi Kiyoi, Shinobu Tsuzuki, Fumihiko Hayakawa
EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity. International journal of hematology (2023)

Fumihiko Hayakawa.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Fumihiko Hayakawa